Evidence map›Paper›PMID 32905777›Full record

ArticleCell reports2020

Hypoxia Triggers the Intravasation of Clustered Circulating Tumor Cells.

Cinzia Donato, Leo Kunz, Francesc Castro-Giner, Aino Paasinen-Sohns, Karin Strittmatter, Barbara Maria Szczerba, Ramona Scherrer, Nunzia Di Maggio, Wolf Heusermann, Oliver Biehlmaier and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers.

0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed
10.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

137 citing papers in PubMed, 228 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Circulating Tumor Cells: Emerging Frontiers in Cancer Technology.Expert reviews in molecular medicine · 2026
    Review
  7. Hotspots and future trends of male breast cancer: a global perspective.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

77 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Cinzia DonatoDepartment of Biomedicine, Cancer Metastasis Laboratory, University of Basel and University Hospital Basel, 4058 Basel, Switzerland.
Leo KunzDepartment of Biosystems Science and Engineering, ETH Zürich, 4058 Basel, Switzerland.
Francesc Castro-GinerDepartment of Biomedicine, Cancer Metastasis Laboratory, University of Basel and University Hospital Basel, 4058 Basel, Switzerland; SIB Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland.
Aino Paasinen-SohnsDepartment of Biomedicine, Cancer Metastasis Laboratory, University of Basel and University Hospital Basel, 4058 Basel, Switzerland.
Karin StrittmatterDepartment of Biomedicine, Cancer Metastasis Laboratory, University of Basel and University Hospital Basel, 4058 Basel, Switzerland.
Barbara Maria SzczerbaDepartment of Biomedicine, Cancer Metastasis Laboratory, University of Basel and University Hospital Basel, 4058 Basel, Switzerland.
Ramona ScherrerDepartment of Biomedicine, Cancer Metastasis Laboratory, University of Basel and University Hospital Basel, 4058 Basel, Switzerland.
Nunzia Di MaggioDepartment of Biomedicine, Cell and Gene Therapy Laboratory, University of Basel and University Hospital Basel, 4056 Basel, Switzerland.
Wolf HeusermannIMCF Imaging Core Facility Biozentrum, University of Basel, 4056 Basel, Switzerland.
Oliver BiehlmaierIMCF Imaging Core Facility Biozentrum, University of Basel, 4056 Basel, Switzerland.
Christian BeiselDepartment of Biosystems Science and Engineering, ETH Zürich, 4058 Basel, Switzerland.
Marcus VetterGynecologic Cancer Center, University Hospital Basel, 4056 Basel, Switzerland; Department of Medical Oncology, University Hospital Basel, 4056 Basel, Switzerland; Breast Cancer Center, University Hospital Basel, 4056 Basel, Switzerland.
Christoph RochlitzDepartment of Medical Oncology, University Hospital Basel, 4056 Basel, Switzerland; Breast Cancer Center, University Hospital Basel, 4056 Basel, Switzerland.
Walter Paul WeberBreast Cancer Center, University Hospital Basel, 4056 Basel, Switzerland; Department of Surgery, University of Basel and University Hospital Basel, 4056 Basel, Switzerland.
Andrea BanfiDepartment of Biomedicine, Cell and Gene Therapy Laboratory, University of Basel and University Hospital Basel, 4056 Basel, Switzerland.
Timm SchroederDepartment of Biosystems Science and Engineering, ETH Zürich, 4058 Basel, Switzerland.
Nicola AcetoDepartment of Biomedicine, Cancer Metastasis Laboratory, University of Basel and University Hospital Basel, 4058 Basel, Switzerland. Electronic address: nicola.aceto@unibas.ch.
University of Basel · CHETH Zurich · CHUniversity Hospital of Basel · CHSIB Swiss Institute of Bioinformatics · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circulating tumor cells (CTCs) are shed from solid cancers in the form of single or clustered cells, and the latter display an extraordinary ability to initiate metastasis. Yet, the biological phenomena that trigger the shedding of CTC clusters from a primary cancerous lesion are poorly understood. Here, when dynamically labeling breast cancer cells along cancer progression, we observe that the majority of CTC clusters are undergoing hypoxia, while single CTCs are largely normoxic. Strikingly, we find that vascular endothelial growth factor (VEGF) targeting leads to primary tumor shrinkage, but it increases intra-tumor hypoxia, resulting in a higher CTC cluster shedding rate and metastasis formation. Conversely, pro-angiogenic treatment increases primary tumor size, yet it dramatically suppresses the formation of CTC clusters and metastasis. Thus, intra-tumor hypoxia leads to the formation of clustered CTCs with high metastatic ability, and a pro-angiogenic therapy suppresses metastasis formation through prevention of CTC cluster generation.

Indexed as

AnimalsCell HypoxiaFemaleHumansMaleMiceNeoplastic Cells, CirculatingProteomics

Identifiers

PMID32905777
PMCPMC7487783
OpenAlexW3084289412

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.